Orient Europharma Co Ltd Asset Resilience Ratio
Orient Europharma Co Ltd asset resilience ratio. Orient Europharma Co Ltd (4120) has an Asset Resilience Ratio of 1.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4120 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Orient Europharma Co Ltd (2015–2024)
Asset resilience ratio of Orient Europharma Co Ltd from 2015 to 2024. This chart shows how Orient Europharma Co Ltd's Asset Resilience Ratio has changed over time. Read Orient Europharma Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Orient Europharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Orient Europharma Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$158.98 Million | 1.28% |
| Total Liquid Assets | NT$158.98 Million | 1.28% |
Asset Resilience Insights
- Limited Liquidity: Orient Europharma Co Ltd maintains only 1.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Orient Europharma Co Ltd Industry Peers by Asset Resilience Ratio
Compare Orient Europharma Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Orient Europharma Co Ltd Asset Resilience Ratio by Year (2015–2024)
Orient Europharma Co Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Orient Europharma Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.95% | NT$457.18 Million ≈ $14.40 Million |
NT$11.57 Billion ≈ $364.53 Million |
+0.20pp |
| 2023-12-31 | 3.75% | NT$405.21 Million ≈ $12.77 Million |
NT$10.81 Billion ≈ $340.63 Million |
+2.30pp |
| 2022-12-31 | 1.45% | NT$151.15 Million ≈ $4.76 Million |
NT$10.43 Billion ≈ $328.61 Million |
+0.43pp |
| 2021-12-31 | 1.02% | NT$95.93 Million ≈ $3.02 Million |
NT$9.40 Billion ≈ $296.26 Million |
-1.52pp |
| 2020-12-31 | 2.54% | NT$207.64 Million ≈ $6.54 Million |
NT$8.16 Billion ≈ $257.07 Million |
+1.51pp |
| 2019-12-31 | 1.04% | NT$81.80 Million ≈ $2.58 Million |
NT$7.87 Billion ≈ $248.03 Million |
-1.33pp |
| 2018-12-31 | 2.37% | NT$171.80 Million ≈ $5.41 Million |
NT$7.24 Billion ≈ $228.09 Million |
-0.22pp |
| 2017-12-31 | 2.59% | NT$172.41 Million ≈ $5.43 Million |
NT$6.65 Billion ≈ $209.63 Million |
-1.78pp |
| 2016-12-31 | 4.37% | NT$283.61 Million ≈ $8.94 Million |
NT$6.49 Billion ≈ $204.35 Million |
-0.56pp |
| 2015-12-31 | 4.94% | NT$270.24 Million ≈ $8.51 Million |
NT$5.47 Billion ≈ $172.47 Million |
-- |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more